Stockreport
Regeneron inks drug pricing deal with Trump, will offer new hearing-loss therapy for free [CNBC]
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
The biotech company will also offer the first hearing-loss gene therapy for free to eligible U.S. patients following regulatory approval of the product. Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump. In this article Regeneron agreed to lower U.S. drug prices for some Americans as part of a deal with President Donald Trump, the White House said on Thursday. The biotech company will also offer the first hearing-loss gene therapy for free to eligible U.S. patients following regulatory approval of the product earlier Thursday. Regeneron is the latest in a string of major drugmakers to make pricing concessions for new and existing medicines under agreements with Trump. Those deals are part of his “most favored nation” effort to tie U.S. drug prices to the lowest ones in other developed nations. The agreements also exempt the companies from tariffs for three years, including Trump's
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | REGN | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
REGN alerts
REGN alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
REGN alerts
High impacting Regeneron Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
REGN
NEWS
NEWS
- Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S. [Yahoo! Finance][Yahoo! Finance]
- 'Two ways of calculating': Trump defends his mathematically impossible calculations on drug prices [Yahoo! Finance][Yahoo! Finance]
- FDA approves first gene therapy for genetic hearing loss [MSNBC.com][MSNBC.com]
- Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.[GlobeNewswire]
- FDA approves first gene therapy for inherited deafness, shown to restore hearing for children with rare condition [CNN][CNN]
- More
REGN
SEC Filings
SEC Filings
- 4/8/26 - Form 8-K
- 4/3/26 - Form 4
- 3/27/26 - Form SCHEDULE
- REGN's page on the SEC website
- More